I. Core Content Analysis
(A) Mounjaro: A Metabolic Revolution with Dual Agonists
As the world’s first GLP-1/GIP dual receptor agonist, Mounjaro works by activating two hormone receptors synergistically. It not only significantly reduces glycated hemoglobin (with an HbA1c reduction of up to 2.3%) but also achieves strong weight loss (an average weight loss of 25 pounds over three years). The latest 2025 cardiovascular outcome trial shows that it reduces all-cause mortality by 16%, especially for patients with chronic kidney disease, it can delay renal function decline and reduce the risk of cardiovascular events. Clinical data indicates that Mounjaro is superior to traditional GLP-1 drugs in reducing blood glucose fluctuations and improving insulin sensitivity, making it the preferred option for patients with obese diabetes.
(B) Ozempic: Comprehensive Upgrade from Glycemic Control to Organ Protection
Ozempic (Semaglutide), a benchmark GLP-1 receptor agonist, added a chronic kidney disease indication in 2025, which can reduce the risk of renal function deterioration by 39%. Its once-weekly injection method and significant weight loss effect (average weight loss of 7-10%) have made it one of the fastest-growing prescribed drugs globally. Uninsured patients can enjoy the first 13 doses for free through the Novo Nordisk copay card, with subsequent doses costing only 25 each. Combined with third-party platforms like SingleCare, the monthly cost can be reduced to 755.
(C) 2025 New Drugs: The Rise of Oral GLP-1 and Dual Agonists
1.Oral Semaglutide (Rybelsus) : The world’s first oral GLP-1 drug, which can achieve an HbA1c reduction of 1.5-2.0% with once-daily administration, while improving blood lipids and blood pressure. Its innovative SNAC absorption enhancer technology breaks through the gastric barrier, providing a new option for patients who are reluctant to take injections.
2.Mazdutide : A domestic GLP-1/GCG dual receptor agonist, phase III data shows an average weight loss of 14% in 48 weeks, while significantly reducing uric acid and liver enzyme levels, becoming a new hope for patients with metabolic syndrome.
3.Long-acting insulin weekly preparations : Such as Gan & Lee Pharmaceuticals’ GZR4 injection, which can provide stable blood glucose-lowering effect with once-weekly injection, reducing the risk of hypoglycemia, especially suitable for patients in need of intensive treatment.
(D) Best CGM for Type 2 Diabetes: The Era of Precise Monitoring with Dexcom G7
With 99% accuracy and a 20-minute hypoglycemia warning function, Dexcom G7 is listed as the preferred CGM system in the 2025 international guidelines. Its core indicator “Time in Range (TIR)” can quantify treatment effects, and the target value for non-pregnant adults should be >70%. For primary medical institutions, through the “monitoring-adjustment-verification” closed-loop management model, CGM can significantly reduce acute complications and optimize insulin dosage.
(E) Solutions for Uninsured Patients to Obtain Semaglutide
1.Copay Cards and Patient Assistance Programs : The Novo Nordisk copay card offers the first 13 doses for free, with subsequent doses at 25 each; patients with an annual income below 40,000 can apply for the Patient Assistance Program (PAP) to receive free drugs.
2.Third-party Discount Platforms : Through SingleCare or GoodRx, uninsured patients can reduce the price of Ozempic to 755 per month and Wegovy to 1,000 per month. Some pharmacies also offer “first prescription free” activities, which need to be consulted with local pharmacies in advance.
(F) Jardiance vs. Farxiga: The Debate on Cardiovascular Protection of SGLT2 Inhibitors
Both reduce blood glucose by promoting urinary glucose excretion, but Jardiance has more sufficient evidence in cardiovascular protection – it reduces the risk of heart failure hospitalization by 27% and is recommended as a first-line drug for patients with comorbid cardiovascular diseases in multiple guidelines. Farxiga, on the other hand, performs prominently in the treatment of chronic kidney disease, reducing the risk of renal failure by 39% and with a slightly lower price (about $17.88 per tablet per month). The latest 2025 data shows that the combination of the two can further improve the blood glucose control compliance rate, but attention should be paid to the risk of genitourinary system infections.
II. Recommendations for Patients
1.Principles for Drug Selection :
◦Obese patients should prioritize GLP-1 drugs (such as Mounjaro, Ozempic) for both blood glucose reduction and weight loss.
◦For those with comorbid cardiovascular diseases or kidney diseases, SGLT2 inhibitors (Jardiance, Farxiga) are better choices.
1.CGM Usage Strategies :
◦Newly diagnosed patients are advised to use Dexcom G7 to establish baseline data, and then adjust the treatment plan according to the TIR value.
◦Primary medical institutions can apply CGM data under the principle of “interpreters being responsible for interpretation”, led by general practitioners.
1.Cost Optimization Paths :
◦Uninsured patients can reduce the annual cost of Semaglutide by more than 70% through the combination strategy of “copay cards + PAP + discount platforms”.
◦Pay attention to limited-time preferential activities on the official websites of pharmaceutical manufacturers (such as Novo Nordisk, Eli Lilly).
III. 2025 Trends in Diabetes Management
1.Popularization of Oral GLP-1 : The launch of Rybelsus marks the end of the injection treatment era, and it is expected that the proportion of global oral GLP-1 prescriptions will exceed 40% by the end of 2025.
2.Dual Agonists Dominating the Market : Multi-target drugs such as Mounjaro and Mazdutide will become first-line treatment options for metabolic syndrome.
3.Precision Medicine Implementation : Through genetic testing and AI algorithms, personalized matching of “drugs – dosage – patients” will be realized, such as selecting the optimal drug according to GLP-1 receptor gene polymorphism.
IV. Conclusion
Diabetes treatment in 2025 has entered a new era of “drug innovation + precise monitoring + cost optimization”. From the dual agonist mechanism of Mounjaro to the real-time blood glucose management of Dexcom G7, from the inclusive policy of copay cards to the convenience of oral GLP-1, patients are ushering in more effective and economical treatment options. It is recommended to communicate regularly with the medical team, and formulate the most suitable long-term management plan based on the latest guidelines and personal health data.